118 related articles for article (PubMed ID: 11216674)
1. Smad protein expression and activation in transforming growth factor-beta refractory human squamous cell carcinoma cells.
Yan W; Vellucci VF; Reiss M
Oncol Res; 2000; 12(3):157-67. PubMed ID: 11216674
[TBL] [Abstract][Full Text] [Related]
2. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis.
Xie W; Bharathy S; Kim D; Haffty BG; Rimm DL; Reiss M
Oncol Res; 2003; 14(2):61-73. PubMed ID: 14649540
[TBL] [Abstract][Full Text] [Related]
3. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.
Xie W; Mertens JC; Reiss DJ; Rimm DL; Camp RL; Haffty BG; Reiss M
Cancer Res; 2002 Jan; 62(2):497-505. PubMed ID: 11809701
[TBL] [Abstract][Full Text] [Related]
4. Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Lange D; Persson U; Wollina U; ten Dijke P; Castelli E; Heldin CH; Funa K
Int J Oncol; 1999 Jun; 14(6):1049-56. PubMed ID: 10339656
[TBL] [Abstract][Full Text] [Related]
5. Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensitivity in carcinoma cells.
Heldin NE; Bergström D; Hermansson A; Bergenstråhle A; Nakao A; Westermark B; ten Dijke P
Mol Cell Endocrinol; 1999 Jul; 153(1-2):79-90. PubMed ID: 10459856
[TBL] [Abstract][Full Text] [Related]
6. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
7. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Muro-Cacho CA; Rosario-Ortiz K; Livingston S; Muñoz-Antonia T
Clin Cancer Res; 2001 Jun; 7(6):1618-26. PubMed ID: 11410498
[TBL] [Abstract][Full Text] [Related]
8. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
9. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
10. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Qiu W; Schönleben F; Li X; Su GH
Cancer Lett; 2007 Jan; 245(1-2):163-70. PubMed ID: 16478646
[TBL] [Abstract][Full Text] [Related]
11. Decreased Smad4 expression in the transforming growth factor-beta signaling pathway during progression of esophageal squamous cell carcinoma.
Fukuchi M; Masuda N; Miyazaki T; Nakajima M; Osawa H; Kato H; Kuwano H
Cancer; 2002 Aug; 95(4):737-43. PubMed ID: 12209716
[TBL] [Abstract][Full Text] [Related]
12. Resistance to transforming growth factor-beta occurs in the presence of normal Smad activation.
Berger DH; Feng XH; Yao J; Saha D; Beauchamp RD; Lin X
Surgery; 2002 Aug; 132(2):310-6. PubMed ID: 12219028
[TBL] [Abstract][Full Text] [Related]
13. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
Baldwin RL; Tran H; Karlan BY
Cancer Res; 2003 Mar; 63(6):1413-9. PubMed ID: 12649207
[TBL] [Abstract][Full Text] [Related]
14. A novel dominant negative Smad2 mutation in a TGFbeta resistant human carcinoma cell line.
Tsang KJ; Tsang D; Brown TN; Crowe DL
Anticancer Res; 2002; 22(1A):13-9. PubMed ID: 12017275
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.
Rosendahl A; Speletas M; Leandersson K; Ivars F; Sideras P
Int Immunol; 2003 Dec; 15(12):1401-14. PubMed ID: 14645149
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
[TBL] [Abstract][Full Text] [Related]
17. Expression of transforming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta1.
Piek E; Westermark U; Kastemar M; Heldin CH; van Zoelen EJ; Nistér M; Ten Dijke P
Int J Cancer; 1999 Mar; 80(5):756-63. PubMed ID: 10048979
[TBL] [Abstract][Full Text] [Related]
18. The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling.
Itoh S; Ericsson J; Nishikawa J; Heldin CH; ten Dijke P
Nucleic Acids Res; 2000 Nov; 28(21):4291-8. PubMed ID: 11058129
[TBL] [Abstract][Full Text] [Related]
19. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma.
Fukuchi M; Fukai Y; Masuda N; Miyazaki T; Nakajima M; Sohda M; Manda R; Tsukada K; Kato H; Kuwano H
Cancer Res; 2002 Dec; 62(24):7162-5. PubMed ID: 12499250
[TBL] [Abstract][Full Text] [Related]
20. Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
Báez A; Cantor A; Fonseca S; Marcos-Martinez M; Mathews LA; Muro-Cacho CA; Muñoz-Antonia T
Clin Cancer Res; 2005 May; 11(9):3191-7. PubMed ID: 15867212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
